

Lerdelimumab

Cat. No.:	HY-P99695
CAS No.:	285985-06-0
Target:	TGF-beta/Smad
Pathway:	Stem Cell/Wnt; TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lerdelimumab (CAT-152) is an IgG4 human anti-TGF- β 2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research ^{[1][2]} .
In Vitro	Lerdelimumab (10 μ g/mL) inhibits all TGF- β 2-induced effects. TGF- β 2 stimulates transdifferentiation and contraction of the capsular bag and induces MMP-2 and -9 release of capsular bags ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Lerdelimumab (100 μ L, 1 mg/mL; subconjunctival injection; on days 2, 3, 4, 7, 9, 11 and 14 after surgery) significantly improves glaucoma surgical outcome and reduces the risk of corneal side effects ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Mead AL, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3394-401.

[2]. Wormstone IM, et al. TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA